Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28440805 | 0.99 | DGAT1 (0.33) | DGAT1CYP2C9TSHR | |
| SCHEMBL20767572 | 0.87 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL25615934 | 0.83 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL25349464 | 0.82 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL21751788 | 0.82 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL21751562 | 0.81 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL20553711 | 0.81 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL31609983 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL28939497 | 0.80 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL25886857 | 0.80 | DGAT1 (0.38) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410190-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250179090-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2025-06-05 | — | — | US | disclosed |
| US-12220419-B2 | BCL-2 inhibitors | NEWAVE PHARMACEUTICAL INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | NEWAVE PHARMACEUTICAL INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-08-31 | — | — | US | disclosed |
| EP-4227311-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116425771-A | Condensed heterocyclic derivatives as Bcl-2 inhibitors for the treatment of neonatal diseases | 广州麓鹏制药有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-3672975-B1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-111448198-B | Condensed heterocyclic derivatives as Bcl-2 inhibitors for the treatment of neonatal diseases | 广州麓鹏制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4110298-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-115484933-A | Hot melt extrusion solid dispersions containing BCL2 inhibitors | 广州麓鹏制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2022-11-24 | — | — | US | disclosed |
| US-20220220126-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2022-07-14 | — | — | US | disclosed |
| US-11279711-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
| WO-2021066873-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200190109-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | NEWAVE PHARMACEUTICAL INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2020041406-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295183-A1 | HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR | BCL2, BCL2L1, BCL2L2 | DGAT1 3779/4885CYP2C9 3027/4885TSHR 4568/4885 |
| US-11680072-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2A1 | DGAT1 4452/4885CYP2C9 2263/4885TSHR 2010/4885 |
| US-11279711-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2L10 | DGAT1 4459/4885CYP2C9 2499/4885TSHR 3254/4885 |
| US-20230271979-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | DGAT1 4459/4885CYP2C9 2499/4885TSHR 3254/4885 |
| US-20250179090-A1 | CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL2L11, BCL2L10 | DGAT1 4503/4885CYP2C9 2743/4885TSHR 3486/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | DGAT1 4227/4885CYP2C9 3167/4885TSHR 3378/4885 |
| US-20200190109-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | DGAT1 4459/4885CYP2C9 2499/4885TSHR 3254/4885 |
| US-12410190-B2 | Condensed heterocyclic derivates as BCL-2 inhibitors for the treatment of neoplastic diseases | BCL2, BCL3, BCL2L10 | DGAT1 4459/4885CYP2C9 2499/4885TSHR 3254/4885 |
| US-12220419-B2 | BCL-2 inhibitors | BCL2L10, BCL2, BCL2L11 | DGAT1 4227/4885CYP2C9 3167/4885TSHR 3378/4885 |
| US-20220372042-A1 | CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS | BCL2L11, BCL2L10, BCL2 | DGAT1 4510/4885CYP2C9 3423/4885TSHR 3684/4885 |
| US-20220220126-A1 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | BCL2, BCL3, BCL2L10 | DGAT1 4459/4885CYP2C9 2499/4885TSHR 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.